Special Issue

Pulmonary Fibrosis and Lung Cancer: Pathophysiology and Novel Therapeutic Approaches

Message from the Guest Editor

Pulmonary fibrosis (PF) is a progressive chronic interstitial lung disease characterized by robust remodeling and scarring of the lung resulting in stiffening of lung vasculature and causes other pathological changes that compromises the lung function. PF is caused by several factors including inflammation, smoke and gene mutation. Despite ongoing efforts to identify a cure, currently, there is no medication for PF and treatment options largely relies on impeding lung scarring with drugs and steroids and lung transplantation being the last resort in severe cases of PF with limited success. This Special Issue aims to provide our readers with the current knowledge and understanding and novel therapeutic approaches for the treatment of PF. We welcome original research articles, reviews, meta-analyses/systematic reviews, or shorter perspective articles, as well novel technological approaches on all aspects related to the pathophysiological, molecular aspects and treatment options of pulmonary fibrosis. For more information, please visit Special Issue website.

Guest Editor

Dr. Arun Samidurai

Pauley Heart Center, Department of Internal Medicine, Cardiology Division, Virginia Commonwealth University, Richmond, VA, USA

Deadline for manuscript submissions

closed (20 June 2025)



Journal of Respiration

an Open Access Journal by MDPI



mdpi.com/si/176545

Journal of Respiration Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jor@mdpi.com

mdpi.com/journal/

jor





Journal of Respiration

an Open Access Journal by MDPI



jor



About the Journal

Message from the Editor-in-Chief

Over the last decade, the amount of information pertaining to thoracic structures has been unprecedented. The thorax is unique in terms of the different structures that involve the respiratory systemlungs, pleura, upper and lower respiratory tract-all located in the mediastinum that by itself represents a different compartment with its own wealth of conditions, and that also includes the Thymic gland. Therefore, we believe that the availability of a new open access journal, JoR, dedicated to highlighting and disseminating information related to the respiratory system is not only timely but is also absolutely necessary. As we can see, the information related to the respiratory systems is vast and there could not be anything more and better than to have a journal that is dedicated to the promotion, dissemination, and efficient publication of timely articles on the respiratory system including all its structures.

Editor-in-Chief

Prof. Dr. Cesar A. Moran Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 30.5 days after submission; acceptance to publication is undertaken in 5.6 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.